With growing evidence suggesting that certain types of diabetes treatments—such as SGLT2 inhibitors or GLP-1 receptor agonists—may mitigate cardiovascular risk in addition to improving glycemic control, the potential dual purpose of these diabetes medications could be considered-despite their higher cost—to optimize treatment decisions in patients with type 2 diabetes at high risk of CVD [24–27]. Here, GLP1R is linked to type 2 diabetes mellitus.